Omeros (NASDAQ:OMER) issued its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04), Fidelity Earnings reports. The business had revenue of $4.61 million during the quarter, compared to analyst estimates of $3.07 million. During the same quarter in the previous year, the business posted ($0.16) EPS.
Shares of NASDAQ OMER opened at $13.02 on Friday. Omeros has a fifty-two week low of $8.36 and a fifty-two week high of $27.00.
In other news, VP Marcia S. Kelbon sold 7,529 shares of the stock in a transaction that occurred on Friday, August 31st. The stock was sold at an average price of $25.75, for a total value of $193,871.75. Following the sale, the vice president now directly owns 227,645 shares in the company, valued at $5,861,858.75. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 12.10% of the company’s stock.
A number of brokerages have issued reports on OMER. ValuEngine downgraded Omeros from a “buy” rating to a “hold” rating in a research report on Saturday. Maxim Group restated a “buy” rating and set a $32.00 price objective on shares of Omeros in a research report on Friday. HC Wainwright set a $34.00 price objective on Omeros and gave the company a “buy” rating in a research report on Wednesday, October 24th. BidaskClub upgraded Omeros from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 17th. Finally, Zacks Investment Research upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $27.56.
TRADEMARK VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/11/11/omeros-omer-issues-earnings-results.html.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Story: Stock Symbols and CUSIP Explained
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.